{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:03:35Z","timestamp":1790215415431,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115176","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:20:06Z","timestamp":1784388006000},"page":"115176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity"],"prefix":"10.1016","volume":"398","author":[{"given":"Sojin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyujin","family":"Kyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongpyo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungwei","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhee","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115176_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115176_bb0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115176_bb0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115176_bb0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115176_bb0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115176_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115190","article-title":"MRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond","volume":"206","author":"Estape Senti","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115176_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymthe.2023.10.024","article-title":"mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer","volume":"32","author":"Malla","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115176_bb0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7150\/thno.89247","article-title":"Path towards mRNA delivery for cancer immunotherapy from bench to bedside","volume":"14","author":"Chen","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115176_bb0045","doi-asserted-by":"crossref","first-page":"xii74","DOI":"10.1093\/annonc\/mdx727","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"Sanchez-Paulete","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.115176_bb0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115176_bb0055","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115176_bb0060","article-title":"Lipid nanoparticles deliver the therapeutic VEGFA mRNA in vitro and in vivo and transform extracellular vesicles for their functional extensions","volume":"10","author":"Nawaz","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.jconrel.2026.115176_bb0065","doi-asserted-by":"crossref","first-page":"E3351","DOI":"10.1073\/pnas.1720542115","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Yanez Arteta","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115176_bb0070","doi-asserted-by":"crossref","first-page":"14935","DOI":"10.2147\/IJN.S565558","article-title":"Key clinical frontiers of mRNA loaded lipid nanoparticles in cancer vaccines","volume":"20","author":"Cao","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115176_bb0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115176_bb0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2026.115176_bb0085","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115176_bb0090","article-title":"Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines","volume":"34","author":"Wang","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2026.115176_bb0095","series-title":"KEYNOTE-942: mRNA-4157\/V940 + Pembrolizumab in Melanoma","author":"Merck Sharp & Dohme Corp","year":"2019"},{"key":"10.1016\/j.jconrel.2026.115176_bb0100","series-title":"A Phase 3, Randomized Study of mRNA-4157 (V940) in Combination with Pembrolizumab Versus Pembrolizumab Alone in Participants with High-Risk Melanoma","author":"Merck Sharp & Dohme LLC","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115176_bb0105","series-title":"An Open-Label, Multicenter Phase I Trial of a Liposomal RNA Vaccine in Patients with Advanced Melanoma","author":"BioNTech SE","year":"2017"},{"key":"10.1016\/j.jconrel.2026.115176_bb0110","series-title":"A Phase I Study of BNT122 (Autogene Cevumeran) in Patients with Solid Tumors","author":"BioNTech SE","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115176_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115176_bib161","article-title":"First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)","volume":"11","author":"Karen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115176_bib162","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00262-022-03245-x","article-title":"Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens","volume":"72","author":"Helen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115176_bb0120","series-title":"A Phase II Study of BNT111 in Combination with Cemiplimab in Patients with Anti-PD-1 Refractory\/Relapsed, Unresectable Stage III or IV Melanoma","author":"BioNTech SE","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115176_bb0125","series-title":"A Phase I Study of BNT116 in Patients with Non-Small Cell Lung Cancer","author":"BioNTech SE","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115176_bb0130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115176_bb0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314166121","article-title":"Inhibition of mRNA nuclear export promotes SARS-CoV-2 pathogenesis","volume":"121","author":"Mei","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115176_bb0140","article-title":"High throughput FISH screening identifies small molecules that modulate oncogenic lncRNA MALAT1 via GSK3B and hnRNPs","volume":"9","author":"Zablowsky","year":"2023","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.jconrel.2026.115176_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41590-018-0052-z","article-title":"Toll-like receptor 9 antagonizes antibody affinity maturation","volume":"19","author":"Akkaya","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115176_bb0150","doi-asserted-by":"crossref","first-page":"26984","DOI":"10.1038\/srep26984","article-title":"The balance between conventional DCs and plasmacytoid DCs is pivotal for immunological tolerance during pregnancy in the mouse","volume":"6","author":"Fang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115176_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/mps5050070","article-title":"Multiparametric flow cytometry-based immunophenotyping of mouse liver immune cells","volume":"5","author":"Vanekova","year":"2022","journal-title":"Methods Protoc."},{"key":"10.1016\/j.jconrel.2026.115176_bb0160","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.4049\/jimmunol.164.6.2978","article-title":"CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen","volume":"164","author":"Vremec","year":"2000","journal-title":"J. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:02:17Z","timestamp":1790211737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S0168365926005791"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115176","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Samyang Biopharm Corporation. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115176"}}